HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sirolimus and Metformin Synergistically Inhibits Colon Cancer In Vitro and In Vivo.

Abstract
We estimated the effect of various immunosuppressants (ISs) and metformin (M) to provide theoretical background of optimal therapeutic strategy for de novo colon cancer after liver transplantation (LT). Three colon cancer cell lines (HT29, SW620, and HCT116) were used in in vitro studies. HT29 was also used in BALB/c-nude mice animal models. Following groups were used in both in vitro and in vivo studies: sirolimus (S), tacrolimus (T), cyclosporin A (CsA), M, metformin/sirolimus (Met/S), metformin/tacrolimus (Met/T), and metformin/cyclosporin A (Met/CsA). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed and western blot analyses were performed for mTOR pathway proteins, apoptosis proteins, and epithelial-mesenchymal-transition (EMT) proteins. Tumor volume was measured for 4 weeks after inoculation. MTT-assay revealed significant cell viability inhibition in all 3 colon cancer cell lines in groups of S, M, and Met/S. Of note, group Met/S showed synergistic effect compare to M or S group. Western blot analysis showed significant low levels of all investigated proteins in groups of S and Met/S in both in vitro and in vivo experiment. Tumor growth was significantly inhibited only in the Met/S group. Combination of Met and S showed the most potent inhibition in all colon cancer cell lines. This finding might have application for de novo colon cancer.
AuthorsNadiar Mussin, Seung Cheol Oh, Kwang Woong Lee, Min Young Park, Sooin Seo, Nam Joon Yi, Hyeyoung Kim, Kyung Chul Yoon, Sung Woo Ahn, Hyo Sin Kim, Suk Kyun Hong, Dong Kyu Oh, Kyung Suk Suh
JournalJournal of Korean medical science (J Korean Med Sci) Vol. 32 Issue 9 Pg. 1385-1395 (Sep 2017) ISSN: 1598-6357 [Electronic] Korea (South)
PMID28776332 (Publication Type: Journal Article)
Copyright© 2017 The Korean Academy of Medical Sciences.
Chemical References
  • Antineoplastic Agents
  • Smad3 Protein
  • Cyclosporine
  • Metformin
  • Ribosomal Protein S6 Kinases, 70-kDa
  • Sirolimus
  • Tacrolimus
Topics
  • Animals
  • Antineoplastic Agents (pharmacology, therapeutic use)
  • Apoptosis (drug effects)
  • Cell Line, Tumor
  • Colonic Neoplasms (drug therapy, pathology)
  • Cyclosporine (pharmacology, therapeutic use)
  • Disease Models, Animal
  • Drug Synergism
  • Drug Therapy, Combination
  • HCT116 Cells
  • HT29 Cells
  • Humans
  • Metformin (pharmacology, therapeutic use)
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Ribosomal Protein S6 Kinases, 70-kDa (metabolism)
  • Signal Transduction (drug effects)
  • Sirolimus (pharmacology, therapeutic use)
  • Smad3 Protein (metabolism)
  • Tacrolimus (pharmacology, therapeutic use)
  • Transplantation, Heterologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: